FR2691465B1 - Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant. - Google Patents

Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.

Info

Publication number
FR2691465B1
FR2691465B1 FR9206361A FR9206361A FR2691465B1 FR 2691465 B1 FR2691465 B1 FR 2691465B1 FR 9206361 A FR9206361 A FR 9206361A FR 9206361 A FR9206361 A FR 9206361A FR 2691465 B1 FR2691465 B1 FR 2691465B1
Authority
FR
France
Prior art keywords
peptide
microsphere
complexes
medicament
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9206361A
Other languages
English (en)
Other versions
FR2691465A1 (fr
Inventor
Dussourd D Hinterland Lucien
Cousse Henri
Pinel Anne-Marie
Martinez Jean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR9206361A priority Critical patent/FR2691465B1/fr
Publication of FR2691465A1 publication Critical patent/FR2691465A1/fr
Application granted granted Critical
Publication of FR2691465B1 publication Critical patent/FR2691465B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FR9206361A 1992-05-25 1992-05-25 Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant. Expired - Fee Related FR2691465B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9206361A FR2691465B1 (fr) 1992-05-25 1992-05-25 Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9206361A FR2691465B1 (fr) 1992-05-25 1992-05-25 Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.

Publications (2)

Publication Number Publication Date
FR2691465A1 FR2691465A1 (fr) 1993-11-26
FR2691465B1 true FR2691465B1 (fr) 1995-08-11

Family

ID=9430134

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9206361A Expired - Fee Related FR2691465B1 (fr) 1992-05-25 1992-05-25 Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.

Country Status (1)

Country Link
FR (1) FR2691465B1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
US5786332A (en) * 1995-03-06 1998-07-28 Trega Biosciences, Inc. Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
US6696417B1 (en) 1997-11-21 2004-02-24 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Skin and hair darkening composition
GB9816234D0 (en) * 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
WO2000032235A1 (fr) * 1998-11-26 2000-06-08 Pentapharm Ag Conjugues systeme de transport
ES2163966B2 (es) * 1999-02-26 2003-07-01 Cantabria Ind Farmaceutica Sa Glicoconjugados constituidos por la asociacion no covalente de polisacaridos con polipeptidos.
EP1593384A3 (fr) * 1999-06-29 2006-04-26 Palatin Technologies, Inc. Compositions pour le traitement de dysfonctionnements sexuels
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
WO2002083176A2 (fr) * 2001-04-17 2002-10-24 University Of Sheffield Vehicule
US6797697B2 (en) 2001-05-21 2004-09-28 Johnson & Johnson Consumer Companies, Inc. Composition containing a peptide and a pigment and the use thereof in darkening the skin
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
DE60221718T2 (de) * 2002-05-24 2008-04-30 Johnson & Johnson Consumer Companies, Inc. Eine, ein peptid und ein pigment enthaltende zusammensetzung und deren verwendung zur hautbräunung
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6509727A (fr) * 1965-07-28 1967-01-30
EP0146113A3 (fr) * 1983-12-15 1987-08-19 Dieter Aderhold Agent actif et composition thérapeutique pour traitement des défaillances de diencéphalon, des maladies nerveuses et des maladies de la peau
IT1204434B (it) * 1986-01-15 1989-03-01 Alfio Bertolini Composizioni farmaceutiche comprendenti frammenti di acth per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria
ATE109793T1 (de) * 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
AU635721B2 (en) * 1988-10-04 1993-04-01 Cancer Research Campaign Technology Limited Targetting agents
IT1229514B (it) * 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.

Also Published As

Publication number Publication date
FR2691465A1 (fr) 1993-11-26

Similar Documents

Publication Publication Date Title
BR9504791B1 (pt) composto de polipeptìdeo e composição farmacêutica.
GB9113219D0 (en) Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
FR2691465B1 (fr) Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
PH30928A (en) Pharmaceutical agents.
ITRM910696A1 (it) Composizioni farmaceutiche per l'applicazione per via nasale.
NL300249I1 (nl) Cefalosporinen en homologen, bereidingen en farmaceutische preparaten.
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
IT1231345B (it) Compressore, dispositivo spruzzatore che lo impiega e nebulizzatore per quest'ultimo
TR27244A (tr) Ilac dagitim aleti.
IT8323396A0 (it) Antimuscarinica. composizione farmaceutica adattivita' sistemica anticolinesterasica, agonista-colinergica ed
EP0672052A1 (fr) Antagonistes de la tachyquinine, leur preparation et leur utilisation dans des formulations pharmaceutiques.
FR2683821B1 (fr) Polysaccharide, polysaccharide neutralise et composition comprenant ce dernier.
EP0608215A4 (fr) Agents antineoplastiques a base de quinobenzoxazine, de quinobenzothiazines et de pyrido-acridine.
ITRM920535A1 (it) Composizione farmaceutica per la somministrazione attraverso le mucose.
EP0592941A3 (fr) Composition de polyamide et utilisation.
EP0586154A3 (fr) Protéine inhibant la production de mélanine, sa préparation et applications.
DE69107742D1 (de) Substituierte 3,7,9-Trioxa-1-aza-2,8-diphosphaspiro[4.5]dekane und stabilisierte Zusammensetzungen.
EP0419157A3 (en) Pharmacologically active compound., preparation and use
ZA933815B (en) Pyrimidinyl- and triazinyl-salicyl- and -picolyl- amides and the use and preparation thereof.
ZA93733B (en) New amidine derivatives, the preparation and use thereof.
HUP9601918A2 (en) N,n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate and pharmaceutical composition containing the same
ITRM920045A0 (it) Composizioni farmaceutiche ad attivita' anti-aging.
IT8819790A0 (it) Peptidi ad attivita' farmaceutica.
ITRM920044A0 (it) Composizioni farmaceutiche ad attivita' anti-aging.
ITRM920043A1 (it) Composizioni farmaceutiche ad attivita' anti-aging.

Legal Events

Date Code Title Description
ST Notification of lapse